Semaglutide and Alzheimer's: The EVOKE Trials and What Actually Happened
Research log — updated after the November 2025 readout. For several years, semaglutide — the GLP-1 receptor agonist behind Ozempic and Wegovy — was one of the most closely watched candidates in Alzheimer's research. Two large Phase 3 trials, EVOKE and EVOKE+, were built to test whether it could slow early Alzheimer's disease. Those trials have now reported. This is a look at why the idea was plausible, what the trials found, and why the honest conclusion is that semaglutide is not an established Alzheimer's treatment.
Why researchers thought it might work
The rationale rested on several converging threads. GLP-1 receptors are present in the brain, and GLP-1 signaling influences neuroinflammation, insulin signaling, synaptic plasticity, and cellular energy handling. Alzheimer's disease has been described by some researchers as "type 3 diabetes" because brain insulin resistance is a recurring feature — so a drug that improves insulin signaling was a mechanistically reasonable thing to try (PMC review).
In preclinical animal models of Alzheimer's, GLP-1 receptor agonists reduced neuroinflammation, improved mitochondrial function, and lowered amyloid-beta plaque and tau tangle burden (PMC). Layered on top of that were epidemiological signals: large real-world analyses of people with type 2 diabetes reported that those on semaglutide or other GLP-1 drugs had meaningfully lower rates of new Alzheimer's diagnoses than people on other diabetes medications — one target-trial-emulation study of over a million U.S. patients reported a 40–70% lower rate of first-time Alzheimer's diagnosis (Alzheimer's & Dementia).
Those are genuinely interesting signals. But observational diabetes data can be confounded, animal models routinely fail to translate, and none of it is the same as a randomized trial in people who already have Alzheimer's. That is exactly the gap EVOKE was designed to close.
What EVOKE and EVOKE+ tested
EVOKE and EVOKE+ were two randomized, double-blind, placebo-controlled Phase 3 trials run by Novo Nordisk. Together they enrolled 3,808 adults aged 55–85 with mild cognitive impairment or mild dementia due to Alzheimer's, all with confirmed amyloid positivity. Participants took oral semaglutide (flexible dosing up to 14 mg once daily) or placebo on top of standard care. The primary endpoint was the change in the Clinical Dementia Rating – Sum of Boxes (CDR-SB) — a standard global measure of cognitive and functional decline — over roughly two years (trial design, PMC).
For a while the expected readout was described as "2025 or 2026." That timeline has now resolved.
The result: the trials did not meet their primary endpoint
On November 24, 2025, Novo Nordisk announced topline results: EVOKE and EVOKE+ did not demonstrate that semaglutide slowed Alzheimer's progression versus placebo on the CDR-SB (Alzheimer Europe; BioSpace). Coverage from NeurologyLive and Neurology Advisor described the drug as not efficacious across the range of global, cognitive, and functional measures.
There were a few nuances worth stating plainly:
Some researchers have pointed to the biomarker changes as a reason to explore semaglutide within combination approaches rather than as a standalone therapy, and fuller data were slated for scientific presentation (ADDF). That is a hypothesis for future study, not evidence of benefit today.
What this means
The straightforward reading: in the largest and most rigorous test to date, semaglutide did not slow early Alzheimer's disease. The earlier epidemiological and preclinical signals — real as they were — did not hold up when tested head-to-head against placebo in people who already had the disease.
Semaglutide remains approved for type 2 diabetes and for weight management; it is not approved for, and has not been shown to treat, Alzheimer's disease. You can read more about the compound itself on our semaglutide reference page, and about approval status generally on our FDA status page. Regulatory and trial information changes over time, so always check primary sources.
This is what evidence-first looks like in practice: a plausible mechanism, encouraging early signals, a definitive trial — and a negative result that we report as clearly as we would have reported a positive one. False hope helps no one, least of all families living with this disease.
PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.